A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.
Patheon announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined, the company reports in a statement.
J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering.
In March 2014, Patheon completed its $2.65 billion merger with DSM Pharmaceutical Products (DPP) to form DPx.
In April 2015, Patheon completed the acquisition of IRIX Pharmaceuticals, a Florence, SC company that specializes in API development and manufacturing. This follows the March 2015 acquisition of Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving drug bioavailability.
Source: Patheon
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.